• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AMRI Hires Vijay Kumar Batra as Managing Director, AMRI India

AMRI Hires Vijay Kumar Batra as Managing Director, AMRI India

January 15, 2014
CenterWatch Staff

Albany Molecular Research, a global contract research and manufacturing organization, has appointed Vijay Kumar Batra to managing director, AMRI India, effective Jan. 2. Batra will report to Steve Hagen, Ph.D., senior vice president of manufacturing and pharmaceuticals.

"Batra brings a wealth of experience in the Active Pharmaceutical Ingredients (APIs) and intermediates business and he also brings a leadership acumen that helps AMRI continue our plan for growth in the Indian and world markets," said Hagen.

Batra held a number of executive roles with Teva Pharmaceuticals Industries since 2003. Most recently, he was vice chairman and managing director, Teva API India, responsible for R&D and manufacturing of API's and advanced intermediates for the global market. The facilities overseen by Batra had strong compliance records and achieved FDA and other international certifications. Batra also was chairman of Teva API China during his most recent tenure. Previously, Batra was president and director of JK Drugs and Pharmaceuticals and advisor at JK Pharmachem. He also held other roles with Ranbaxy, Kinetics Technology India and Synthetics and Chemicals. Batra also was responsible for drug product manufacturing and was vice chairman of Tevapharm India during his last few years.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing